Cargando…

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

BACKGROUND: Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), has been shown to increase the efficacy of endocrine therapies in hormone receptor (HR)-positive metastatic breast cancer. However, because breast cancer is a highly heterogeneous disease, the responses of different patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Zongbi, Ma, Fei, Liu, Binliang, Guan, Xiuwen, Li, Lixi, Li, Chunxiao, Qian, Haili, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515626/ https://www.ncbi.nlm.nih.gov/pubmed/31088410 http://dx.doi.org/10.1186/s12885-019-5668-3

Ejemplares similares

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
por: Yi, Zongbi, et al.
Publicado: (2020)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer
por: Mo, Hongnan, et al.
Publicado: (2020)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study
por: Liu, Binliang, et al.
Publicado: (2018)

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
por: Yi, Zongbi, et al.
Publicado: (2017)

Identification of effective natural PIK3CA H1047R inhibitors by computational study
por: Liu, Naimeng, et al.
Publicado: (2021)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines
por: Guan, Xiuwen, et al.
Publicado: (2016)

Investigating the Structure and Dynamics of the PIK3CA Wild-Type and H1047R Oncogenic Mutant
por: Gkeka, Paraskevi, et al.
Publicado: (2014)

Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

The molecular tumor burden index as a response evaluation criterion in breast cancer
por: Yi, Zongbi, et al.
Publicado: (2021)

PIK3CA(H1047R)-induced paradoxical ERK activation results in resistance to BRAF(V600E) specific inhibitors in BRAF(V600E) PIK3CA(H1047R) double mutant thyroid tumors
por: Roelli, Matthias A., et al.
Publicado: (2017)

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin
por: Cufí, Sílvia, et al.
Publicado: (2013)

Generation of a tree shrew breast cancer model using lentivirus expressing PIK3CA-H1047R
por: Zeng, Li, et al.
Publicado: (2023)

Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation
por: Bian, Ji-Lai, et al.
Publicado: (2017)

Highly sensitive detection of the PIK3CA(H1047R) mutation in colorectal cancer using a novel PCR-RFLP method
por: Li, Wan-Ming, et al.
Publicado: (2016)

Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations
por: Yuan, W, et al.
Publicado: (2013)

Recurrent PIK3CA H1047R-Mutated Congenital Infiltrative Facial Lipomatosis: A Case Report and Review of Literature
por: Oh, Kei Shing, et al.
Publicado: (2023)

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy
por: Ma, Fei, et al.
Publicado: (2016)

DMBA induced mouse mammary tumors display high incidence of activating Pik3ca(H1047) and loss of function Pten mutations
por: Abba, Martín C., et al.
Publicado: (2016)

Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation
por: Bleckmann, Annalen, et al.
Publicado: (2020)

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China
por: Yi, Zongbi, et al.
Publicado: (2020)

A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation
por: Kalofonou, Melpomeni, et al.
Publicado: (2020)

Somatic Mutation of PIK3CA (H1047R) Is a Common Driver Mutation Hotspot in Canine Mammary Tumors as Well as Human Breast Cancers
por: Lee, Kang-Hoon, et al.
Publicado: (2019)

PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
por: Loi, Sherene, et al.
Publicado: (2013)

Physiological Levels of Pik3ca (H1047R) Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors
por: Tikoo, Anjali, et al.
Publicado: (2012)

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
por: Loi, Sherene, et al.
Publicado: (2019)

DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis
por: Rong, Guohua, et al.
Publicado: (2021)

NODAL/TGFβ signalling mediates the self-sustained stemness induced by PIK3CA(H1047R) homozygosity in pluripotent stem cells
por: Madsen, Ralitsa R., et al.
Publicado: (2021)

Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R
por: Meyer, D S, et al.
Publicado: (2013)

Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
por: Raphael, Ari, et al.
Publicado: (2022)

Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells
por: Guan, Xiuwen, et al.
Publicado: (2016)

PIK3CA(H1047R) and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling
por: Cheng, Hailing, et al.
Publicado: (2015)

Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients
por: Liu, Binliang, et al.
Publicado: (2020)

S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis
por: Yuan, Wenlin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k6u3b6ie1b5kj8apoters0s6np